Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Pulmonary Hypertension of Newborn
Interventions: INOmax; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 27 Weeks to 40 Weeks
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Pre-eclampsia, Pregnancy, Post Partum
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle, Glaucoma
Interventions: iStent Inject Implantation; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Phoenix, Arizona • Torrance, California • Dallas, Texas

Conditions: Pulmonary Hypertension
Interventions: Nitric Oxide/INP Pulse Delivery, Nitric Oxide/INO Pulse Delivery; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension, Impaired Glucose Tolerance
Interventions: AR9281, Placebo; Drug
Lead sponsor: Arete Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 30
States / cities: Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more

Conditions: Hypertension
Interventions: Firibastat, Placebo; Drug
Lead sponsor: Quantum Genomics SA; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more

Conditions: Salt-Sensitivity of Blood Pressure
Interventions: Furosemide (Diuretic), Hypertonic Saline Infusion; Drug · Other
Lead sponsor: University of Delaware; Other
Eligibility: 40 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Pre-Eclampsia, Obesity, Gestational Diabetes, Gestational Hypertension
Interventions: Women's Health Delaware Food Farmacy, Usual Standard of Care; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Sepsis, Infection, Septic Shock
Interventions: HBP lab test; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 1,055 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Hypertension
Interventions: Concord Grape Juice; Dietary Supplement
Lead sponsor: Boston University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: baxdrostat (formerly CIN-107) oral solution; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Interventions: ECG-based AI Device - Results Returned to Investigator, Echocardiogram and Right Heart Catheterization, ECG-based AI Device - Results Not Returned to Investigator; Device · Procedure
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Interventions: Non-invasive hemodynamic measurements; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension;Pulmonary;Primary
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 6 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Disease, Hypertension, Diabetes, Obesity
Interventions: Lay Health Promoter (LHP) with maintenance; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 392 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Obesity, Cardiovascular Disease, High Blood Pressure
Interventions: In Person, At Home; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Provider Education, Hypertension Alert, Patient Education; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 90 Years
Enrollment: 1,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Arterial Hypertension
Interventions: Carvedilol, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pediatric Pulmonary Hypertension
Interventions: Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Months to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more

Conditions: Cardiovascular Diseases
Interventions: Fruit and vegetable supplement, Dietary and chronic disease management education; Dietary Supplement · Behavioral
Lead sponsor: St. Catherine University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Apple Valley, Minnesota • Fridley, Minnesota • Minneapolis, Minnesota + 1 more

Conditions: Preeclampsia, Gestational Hypertension
Interventions: spironolactone 25 mg orally once daily, Placebo tablet to match spironolactone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Search by objective public record fields.

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Gestational Changes in Hemodynamics and Respiratory Mechanics in Association With Pre-Eclampsia

iStent Inject New Enrollment Post-Approval Study

Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

Firibastat in Treatment-resistant Hypertension

Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study

Evaluating the Effectiveness of a Food is Medicine Community Health Worker Program for Pregnant Women

Evaluation of the Heparin Binding Protein Levels in Sepsis

Blood Pressure Lowering Effects of Grape Juice

Baxdrostat Bioavailability and Bioequivalence Study

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH

Patient-Provider Communication and Medication Adherence

Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

The GoodNEWS Lifestyle Enhancement Program

Healthy Bodies, Healthy Hearts: A Physical Activity Intervention Trial

Improving Practice Patterns for the Treatment of Hypertension

Beta-blockers in Pulmonary Arterial Hypertension

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

Increased Access to Fruits and Vegetables for Hypertension in Immigrant Hispanic/Latinx Individuals

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories